Sugi Predict

Sugi Predict / Compounds / SCHEMBL4518136

SCHEMBL4518136

SCHEMBL4518136

Cc1cccc(C)c1OCC(C)NS(=O)(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 2/20 0.64
▸ NR3C2 P08235 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.44
▸ MAPT P10636 1/20 0.44
▸ SLC1A2 P43004 1/20 0.44
▸ SCN4A P35499 7/20 0.42
▸ CYP2D6 P10635 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ SCN1A P35498 2/20 0.42
▸ SCN5A Q14524 2/20 0.42
▸ SCN9A Q15858 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ NFKB1 P19838 2/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ KCNK3 O14649 1/20 0.42
▸ CACNA1F O60840 1/20 0.42
▸ KCNK2 O95069 1/20 0.42
▸ GBA1 P04062 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4503992 0.89 NR3C1 (0.57) NR3C1NR3C2ALDH1A1SCN4ACYP2D6
SCHEMBL4516008 0.89 NR3C1 (0.59) NR3C1MAPTSLC1A2SCN4ACYP2D6
SCHEMBL4515277 0.85 NR3C1 (0.63) NR3C1ALDH1A1SCN4ACYP2D6LMNA
SCHEMBL4506870 0.84 NR3C1 (0.62) NR3C1ALDH1A1SLC1A2CA12CA9
SCHEMBL13889015 0.84 NR3C1 (0.62) NR3C1ALDH1A1SLC1A2SCN4ACYP2D6
SCHEMBL4518778 0.82 NR3C1 (0.57) NR3C1ALDH1A1SCN4ACYP2D6LMNA
SCHEMBL13889013 0.81 NR3C1 (0.59) NR3C1MAPTSCN4ACYP2D6LMNA
SCHEMBL4503415 0.81 NR3C1 (0.59) NR3C1SCN4ACYP2D6LMNASCN1A
SCHEMBL4517989 0.81 NR3C1 (0.59) NR3C1SLC1A2SCN4ACYP2D6LMNA
SCHEMBL4526843 0.81 NR3C1 (0.59) NR3C1ALDH1A1SCN4ACYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 — — US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 — — US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 — — US disclosed
EP-1807391-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 — — EP disclosed
WO-2006046916-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885NR3C2 2/4885ALDH1A1 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.